Amicus Therapeutics is a biotechnology company focused on developing innovative therapies for rare and orphan diseases, particularly genetic disorders

Their primary emphasis lies in the advancement of treatments for conditions such as Pompe disease and Fabry disease. The company utilizes proprietary technologies to create enzyme replacement therapies and small molecule pharmacological chaperones, aiming to address unmet medical needs and improve the lives of patients with these challenging conditions. Through a commitment to research and development, Amicus Therapeutics seeks to make significant strides in the field of precision medicine.